The hospital’s chief medical officer resigned last month after failing to disclose company ties in medical journals. Now, Memorial Sloan Kettering researchers, including chief executive Dr. Craig B. Thompson, are updating their own conflict-of-interest disclosures.
A Baylor St. Luke’s Medical Center physician alleges in a lawsuit that hospital officials retaliated against him for expressing concerns about ICU care. The Houston hospital has denied the allegation in court filings.
With its employee health plan in financial crisis, Montana hired a former insurance insider who pushed back against industry players with vested interests in keeping costs high. She proved, essentially, that bargaining down health care prices works.
A vice president at Memorial Sloan Kettering received a stake of nearly $1.4 million in a biotech company for representing the hospital on its board. He will give back his stake as the cancer center grapples with questions about conflicts of interest.
The revised rules, proposed this week as part of the agency’s efforts to reduce “burdensome” federal regulations, would no longer penalize hospitals if too many of their patients die following transplants. St. Luke’s in Houston recently lost its Medicare funding for heart transplants for that very reason.
A for-profit venture with exclusive rights to use the cancer center’s vast archive of tissue slides has generated concerns among pathologists at the hospital, as well as experts in nonprofit law and corporate governance.
A ProPublica analysis found that black people and Native Americans are under-represented in clinical trials of new drugs, even when the treatment is aimed at a type of cancer that disproportionately affects them.
Dr. José Baselga, the hospital’s chief medical officer, stepped down days after a report by ProPublica and the New York Times that he failed to disclose millions of dollars in payments from the health care and drug industry in research articles.
A senior official at Memorial Sloan Kettering Cancer Center has received millions of dollars in payments from companies that are involved in medical research. His omissions expose how weakly conflict-of-interest rules are enforced by journals.
Notes released by a federal agency indicate that one of the hospital’s top heart transplant doctors spoke about “a retiring surgeon” who “wouldn’t stop performing transplants” in explaining a rash of patient deaths. Only Dr. O.H. “Bud” Frazier matches that description.
Carolyn Dineen King, a senior U.S. Circuit Court judge, resigned from the St. Luke’s board on May 30, two weeks after ProPublica and the Houston Chronicle detailed deaths and complications in the famed heart program.
ProPublica and the Houston Chronicle reported in May that Dr. O.H. “Bud” Frazier had often failed to disclose his payments from medical device makers in articles he authored. Since then, he’s amended his disclosures for three pieces in the New England Journal of Medicine.
Without any public scrutiny, insurers and data brokers are predicting your health costs based on data about things like race, marital status, how much TV you watch, whether you pay your bills on time or even buy plus-size clothing.
The state began investigating Barry Helfmann after a 2015 article by ProPublica and the New York Times about debt collection lawsuits against his patients that included details of their mental health diagnoses and treatments.
As ProPublica updates Dollars for Docs, we found that drugmakers spent less money to market opioids to doctors in 2016 than in prior years. Studies have shown that payments to doctors by opioid makers are linked to more prescribing of the drugs.
As pharma companies underwrite three-fourths of the FDA’s budget for scientific reviews, the agency is increasingly fast-tracking expensive drugs with significant side effects and unproven health benefits.
“I sort of feel like we’ve been left in the dark,” says one patient’s wife, who learned from a reporter — and not the Houston hospital — about the program’s temporary suspension. An expert says it will likely take much longer than 14 days to fix.
Over decades, Bud Frazier has played a leading role in the development of mechanical heart pumps and an artificial heart. Out of public view, he’s been accused of putting his quest to make history ahead of the needs of some patients.
The hospital and its legendary surgeon Denton Cooley performed some of the world’s first heart transplants back in the 1960s. In recent years, though, it has had some of the worst heart transplant outcomes in the country.
Baylor St. Luke’s in Houston was known for handling complex heart transplants. But when Travis Hogan was a patient there, he didn’t know that the program was undergoing a series of dramatic changes. He never got his heart.
A study in Washington state found that in a single year more than 600,000 patients underwent treatment they didn’t need, at an estimated cost of $282 million. “Do no harm” should include the cost of care, too, the report author says.
This year ProPublica documented the many ways waste is baked into our health care system, from destroying perfectly good medication to junking brand new supplies. Eliminating the waste could insure millions of Americans.
As insurers ask consumers to pay a greater share of their drug costs, it may be cheaper to pay cash than use your insurance card. One expert estimates that consumers could be overpaying for as many as 1 in 10 prescriptions.
BuzzFeed’s Rosalind Adams set out to learn why America’s largest psychiatric hospital chain was under investigation. Source by source, she built a case that Universal Health Services was locking up people for profit.
Another lawmaker is asking insurers whether their policies have made it easier for patients to access cheaper, more addictive drugs over less addictive alternatives. Meanwhile, the insurance industry trade group pledged additional steps to combat inappropriate prescribing.
The move follows a story by ProPublica and The New York Times detailing how insurance companies and pharmacy benefit managers have made it easier to get opioid painkillers than less risky alternatives.
Medicare patients in Hawaii take fewer opioid painkillers and fewer antibiotics, on average, than those in any other state. Physicians and health policy experts cite demographics and healthier lifestyles as possible reasons why.
Medicare’s popular prescription-drug program serves more than 42 million people and pays for more than one of every four prescriptions written nationwide. Use this tool to find and compare doctors and other providers in Part D in 2015.
Outcry has been building over the rising cost of brand-name medications, but the price of generic drugs has been moving in the opposite direction. The stock prices of generic manufacturers have tumbled, but many consumers aren’t paying less at the pharmacy counter.
Faced with competition, some pharmaceutical companies are cutting deals with insurance companies to favor their brand-name products over cheaper generics. Insurers pay less, but sometimes consumers pay more.
Reversing course, federal health officials withdrew a proposal that would have required private accrediting organizations to publicly release reports of problems they found in health care facilities. Accreditors and hospitals had panned the idea; consumer advocates and business groups supported it.
We’ve heard from 3,100 women who survived life-threatening complications of pregnancy or childbirth. They told us what they wish they had known — and what they would say to other new and expectant mothers.
For years, Vietnam vets and their widows have been pushing the VA to extend benefits to those exposed to the toxic herbicide and later stricken with glioblastoma. The VA has said no, but advocates hope the agency will now revisit the issue.
Some Medicare beneficiaries are being prescribed opioids by 10 or more doctors, or are filling prescriptions for more than 1,000 pills a month. Hundreds of doctors appear to be prescribing indiscriminately, says the inspector general of Health and Human Services.
Pharmaceutical companies are increasingly agreeing to refund money if patients don't respond to medications as expected. The Trump administration is intrigued, but critics say the deals are unlikely to reduce consumers’ bills.
Thank you for your interest in republishing this story. You are are free republish it so long as you do the following:
You can’t edit our material, except to reflect relative changes in time, location and editorial style. (For example, “yesterday” can be changed to “last week,” and “Portland, Ore.” to “Portland” or “here.”)
If you’re republishing online, you have to link to us and to include all of the links from our story, as well as our PixelPing tag.
You can’t sell our material separately.
It’s okay to put our stories on pages with ads, but not ads specifically sold against our stories.
You can’t republish our material wholesale, or automatically; you need to select stories to be republished individually.
You cannot republish our photographs without specific permission (ask our Public Relations Director Minhee Cho if you’d like to).
You have to credit us — ideally in the byline. We prefer “Author Name, ProPublica.”
Copy and paste the following into your page to republish: